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Multi-drug resistance (MDR) occurs when cancer cells become resistant to multiple
chemotherapeutic drugs that are functionally and structurally different. MDR typically leads to
chemotherapy treatment failure and, subsequently, poor patient prognosis. Cancers can become
resistant to antineoplastic drugs by overexpressing one or more ATP-binding cassette (ABC)
transporters that act as drug efflux pumps and expel xenobiotics from cells. One such protein is
the Breast Cancer Resistance Protein (BCRP, or ABCG2), which is believed to confer MDR to
several types of cancer. Inhibition of BCRP cellular activity is therefore thought as a way to
restore sensitivity of MDR cancers to chemotherapeutics.
In previous work, several potential inhibitors of ABC transporters were identified using
high-throughput in silico screens (Brewer et al., 2014). Using cell viability and cellular
accumulation assays of BCRP substrates, we assessed these compounds for toxicity to cells and
the ability to reverse MDR in the BCRP overexpressing breast cancer cell line, MCF7-M100
(Nanayakkara, 2019). Here, cell culture studies of the potential BCRP inhibitors are expanded to
two other cell lines, the BCRP overexpressing colon cancer and BCRP overexpressing non-small
cell lung cancer cell lines, S1M1-80 and MX20, respectively. For each cell line, the level of
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BCRP overexpression was assessed at RNA and protein levels and the MDR phenotype was
confirmed using cell viability assays. Ability of the compounds to reverse MDR was assessed, as
well as the compounds’ toxicity to the cancer cells. Though differences in cell lines were
observed, including passage number effects between low and high passage MCF7-M100 cells,
three compounds seem to be promising candidates as BCRP mediated MDR reversal agents.
Also presented here is work involving another medically relevant ABC transporter, Pglycoprotein (P-gp, or ABCB1), which, in addition to its role in MDR cancers, is also expressed
at the blood-brain barrier (BBB). The BBB protects the brain from xenobiotics and toxins; one
way this is accomplished is by the expression of ABC transporters on the luminal side of the
BBB which expel toxins from the brain. This expelling action becomes an issue with drug
delivery to the brain when treating diseases such as epilepsy and brain cancers. A group of
compounds were tested in the brain capillary endothelial cell line hCMEC/d3 for their ability to
modulate the action of P-gp at the BBB. These compounds seem to be promising candidates for
further research into inhibiting ABC transporters at the blood-brain barrier.
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CHAPTER 1
INTRODUCTION

1.1: ABC Transporters and Multidrug Resistance
Though there exist many chemotherapeutic treatments for cancer patients that have led to
increased survival short-term, long-term survival rates are not as high due largely in part to a
phenomenon called multidrug resistance, or MDR, a phenotype first described in 1970 (Biedler
and Riehm, 1970). Though MDR was a term first used to describe antibiotic-resistant infections,
it is also now used to describe when cancers are resistant to more than one chemotherapeutic
drug. The various drugs can often have completely different structures and mechanisms of
action. It seems that many mechanisms can contribute to MDR, making it both difficult to study
and to overcome (Baguley, 2010).
Common MDR mechanisms are usually divided into three categories: drug dependent,
target dependent, and drug/target dependent. A major contributing factor to drug dependent
MDR is the overexpression of efflux drug transporters, particularly ATP-binding cassette, or
ABC, transporters. These membrane proteins in humans include 48 members classified into
seven subfamilies (ABC-A through ABC-G). ABC transporters are membrane proteins
consisting of transmembrane domains (TMDs) and nucleotide-binding domains (NBDs). In the
NBDs, located at the cytoplasmic side of the cell, ATP is bound and hydrolyzed in order to
provide energy for a conformational change of the protein, which effluxes physiological and
xenobiotic substrates from the cytoplasm to the extracellular space (Chen et al., 2016).
1

There are many approaches to overcoming ABC transporter mediated MDR such as
designing novel drugs that evade efflux (Coley, 2008 and Nobili et al., 2011), inhibitors to block
the pumps (Palmeira et al., 2012), and compounds that selectively kill MDR cells but not the
parental non-resistant cancer cells from which the MDR cells are derived. The latter strategy is
known as collateral sensitivity, and it is created due to genetic alterations formed while creating
resistance to one agent and forming hypersensitivity towards another agent (Pluchino et al.,
2012).
Some of the most clinically relevant and well-studied human ABC transporters include Pglycoprotein (P-gp, also ABCB1) and Breast Cancer Resistance Protein (BCRP, also ABCG2)
(Li et al., 2016).

1.2: Breast Cancer Resistance Protein
1.2.1: Background
BCRP was first described in 1998, making it one of the most recently discovered ABC
transporters. It was originally found to play a role in the drug resistant phenotype in MCF7AdrVp cells, which are breast cancer cells made multidrug resistant by exposure to non-lethal
concentrations of the chemotherapeutics doxorubicin and verapamil. The group who discovered
and began characterizing BCRP suspected that it may be part of a multiprotein complex (Doyle
et al., 1998).
Though BCRP is mostly studied in the context of multidrug resistance in cancer, it is also
present and seems to play important roles in many normal tissues as well (Fetsch et al., 2003). It
is found on the apical side of epithelial cells in the gastrointestinal tract and liver canalicular
membranes, suggesting the protein has a role in protecting against xenobiotic absorption and
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excreting toxic metabolites. BCRP is also found in the placenta, suggesting a similar protective
role for the fetus against toxins ingested by the mother. Finally, BCRP is thought to play an
important role at the blood-brain barrier (BBB), which will be introduced later (Mo and Zhang,
2012 and Fetsch et al., 2003).

1.2.2: Structure
As hypothesized by Doyle et al. (1998) earlier, BCRP was found to be a half-transporter,
meaning that it contains only one nucleotide binding domain (NBD) and one transmembrane
domain (TMD) and must homodimerize or even homo-oligomerize to be functional (Mo and
Zhang, 2012). It is interesting to note that homo-oligomerization is completed only partially by
the formation of intermolecular disulfide bonds; it seems dimers assembled in the membrane are

Figure 1.1: Structure of BCRP.
Cartoon of BCRP bound to substrate estrone-3-sulfate (E1S) in a pre-translocation state (left) and
binding ATP and releasing the substrate (right). One BCRP monomer is colored in blue and the
other in orange. Spheres represent ATP, Mg2+, and E1S. Modified from Manolaridis et al., 2018.
3

mostly reliant on protein-protein interactions (Mao and Unadkat, 2014). A high-resolution
structure has only recently been determined due to challenges in overexpressing and functionally
purifying the protein (Jackson et al., 2018). Presented in Figure 1.1 is a cartoon of BCRP
expelling a substrate.

1.2.3: Role in Multidrug Resistance
Cancer cells can adapt to overexpress ABC transporters, which contributes to MDR. This
is particularly an issue with these protein pumps, as they are relatively non-specific. BCRP has
been shown to transport substrates of widely varying structures and functions including but not
limited to antivirals, chemotherapy drugs, and antibiotics (Chen et al., 2016). Additionally,
BCRP substrate specificity is different yet over-lapping with substrates of P-gp (Haimeur et al.,
2004).
BCRP is associated with many hematologic malignances due to it being often highly
expressed in malignant hematopoietic and lymphoid cells. In particular, BCRP is implicated in
both acute and chronic myelogenous leukemia, acute lymphoblastic leukemia, and possibly
lymphoma (Natarajan et al., 2012). BCRP’s role in solid tumors is currently under active
investigation, but it seems it might play a role in a wide variety of tumors including breast
cancers, brain cancers, lung cancers, and head and neck carcinomas (Thomas-Schoemann et al.,
2014).

4

1.3: P-glycoprotein
1.3.1: Background
P-glycoprotein (P-gp), or ABCB1, was the first identified human ABC transporter (Safa
et al., 1986). It is arguably the best studied ABC transporter, especially in relation to MDR. P-gp,
like BCRP, has a broad range of substrates including amphipathic, lipid soluble, and some
aromatic compounds. It transports drugs such as taxanes, anthracyclines, HIV-protease
inhibitors, and antibiotics. P-gp is a single polypeptide consisting of two nucleotide binding
domains (Kim and Chen, 2018).
P-gp has a general function outside of MDR to protect cells against xenobiotics and
toxins. The protein is found in the intestine mucosal membrane, kidney epithelia, liver, and
placenta (Chen et al., 2016).

1.3.2: Previous Success in Discovering and Designing Novel P-gp Inhibitors
In previous work, our lab has taken a novel approach when looking for inhibitors of P-gp
and, more recently, BCRP. High-throughput, parallel in silico ligand docking studies were
conducted, specifically focusing on identifying reversible inhibitors of ATP hydrolysis at the
nucleotide binding domains (NBDs) of P-gp using a P-gp homology model (Brewer et al., 2014).
The NBD was targeted due to the hypothesis that previous inhibitors of P-gp may have failed
partially because they targeted the highly non-specific drug binding domains. This may be
problematic because binding of any drug to the drug binding domain (DBD) may result in it
being pumped out of cells by the protein, therefore likely requiring increased systemic
concentrations of the drugs and resulting in off target toxicities. From the docking study, 250
compounds were predicted to bind strongly to NBDs but less strongly at DBDs of P-gp, and 35
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of those were initially analyzed in biochemical assays. Four compounds showed significant
inhibition of stimulated ATP hydrolysis including SMU-19, 29, 34, and 45 (Brewer et al., 2014).
After these initial findings, these novel compounds were assessed using cell culture
methods involving drug resistant as well as naïve cancer cells that indicated that compounds 29,
34, and 45 restored sensitivity of an MDR prostate cancer cell line to the chemotherapeutics
paclitaxel and doxorubicin to a level comparable to the parental, non-MDR cancer line (Follit et
al., 2015). Using other methods, the group determined that it is likely that these compounds
directly interact with NBDs of P-gp (Brewer et al., 2014), and that these compounds were not
cytotoxic to noncancerous cells at concentrations where multidrug resistance was reversed in the
cancer cells (Follit et al., 2015). The work was extended to an MDR ovarian cancer cell line, and
it was confirmed that the compounds specifically inhibited P-gp function and increased
accumulation of substrates in both MDR cancer cell lines (Nanayakkara et al., 2018).
Using computer-aided, structure-based approaches other compounds were developed that
still satisfied the aforementioned characteristics but were structural variants of compound 29.
This approach was compared to rationally designed 29 variants, and a group of these 29 variants
was synthesized and tested for MDR reversal. All of the computationally evaluated variants
performed better than even 29 and were found to not be substrates of P-gp while only one of the
rationally designed variants was not a substrate (Wise et al., 2019).
To expand the research to the discovery and development of inhibitors also to the second,
medically relevant toxin pump, our group then developed an MDR breast cancer cell line that
overexpressed BCRP. Potential inhibitors of P-gp and BCRP discovered in computational
searches similar to (Brewer et al., 2014) were assessed in the lab using this BCRP
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overexpressing breast cancer cell line. The work presented here extends the BCRP studies using
different BCRP overexpressing cancer cell lines as well as the parental, naïve cell lines.

1.4: BCRP and P-gp in the Blood-Brain Barrier
BCRP and P-gp are also found in higher concentrations at the blood-brain barrier (BBB)
(Chaves et al., 2014). This selective barrier regulates the exchange of substances between the
blood and the brain, especially protecting the brain by limiting the entrance of and expelling
toxins. The BBB is comprised of specialized brain microvascular endothelial cells attached by
tight junctions. The endothelial cells’ specialized phenotype is maintained by cells present in the
brain including pericytes, astrocytes, neurons, and microglia (Gomez-Zepeda et al., 2019).
The ABC transporters are primarily responsible for expelling toxins from the brain. P-gp
and BCRP, among a few other ABC transporters, are present at the luminal side of the BBB.
Though these proteins seem to be acting as “good guys,” they can also be negative players in
some cases. For example, delivery of drugs to the brain is difficult due in part to the presence of
the ABC transporters, and this limited delivery is a common cause of therapeutic failure in
epilepsy (Miller, 2010). This is also an issue with brain cancers. It is reported that only about 5%
of the free mitoxantrone (a common chemotherapeutic for lymphoma) actually crosses the BBB,
and similar low brain penetration was found in the treatment of gliomas. However, when BCRP
is knocked-out, the extrusion of mitoxantrone was shown to be significantly decreased (Iorio et
al., 2016).
Thus, research into therapeutic approaches for inhibiting P-gp and/or BCRP has been and
continues to be important. However, no treatments have made it to clinical studies, mostly
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because many adverse effects have been observed such as toxicity and inhibition of too many
transporters, leading to accumulation of toxins inside cells (Gomez-Zepeda, 2019).

1.5: Rationale/Purpose
There are many different approaches groups are taking to study and overcome ABC
transporter mediated MDR. One of the biggest goals is to develop inhibitors of one or more
transporters, which will then allow chemotherapeutics to enter and remain in the cancer cells.
However, this has proved to be challenging due to a variety of reasons including that many of the
MDR reversal agents are discovered to be pump substrates, meaning they do not specifically
modulate ABC transporters, or the agents are toxic to the organism (Chen et al., 2016).
Testing drugs for their ability to inhibit ABC transporters requires several steps. First,
selected MDR cancer cells lines must be evaluated for their overexpression of ABC transporters,
particularly P-gp and BCRP. This should be done at both the RNA and protein levels. It is ideal
that the cell lines specifically overexpress one transporter in order to conduct studies with the
purpose of inhibiting only one transporter at a time. Next, a model for the MDR phenotype for
those cell lines should then be established in order to confirm that the cell lines will make a
feasible model for potential inhibitor studies. Finally, the MDR cell lines could then be used for
testing potential inhibitors and MDR reversal agents.
Thus, if a compound can be found that significantly and specifically inhibits an ABC
transporter such as P-gp or BCRP without being a substrate for that transporter or toxic to regular
cells, treatment for chronic or reoccurring cancers would be impacted in a major way. This
would also have implications at the BBB, such as providing a possible avenue for other drugs to
enter the brain to treat diseases such as epilepsy and brain tumors.
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CHAPTER 2
MATERIALS AND METHODS

2.1: Quantitative Real-Time Polymerase Chain Reaction
As part of the cell line characterization studies, quantitative real-time polymerase chain
reaction (qRT-PCR) was performed in order to measure the level of ABC transporter RNA
present in the supposedly BCRP overexpressing cancer cells compared to their parental cell
lines. RNA was extracted from S1 (parental human colon cancer), S1M1-80 (MDR version of
S1), H460 (parental human non-small cell lung cancer), MX20 (MDR version of H460), MCF7
(human parental breast cancer), and M100 (MDR version of MCF7) cells using the Aurum Total
RNA Mini Kit (Bio-Rad) following the Spin Protocol that accompanies the kit. 2 million cells
per cell sample were used. The extracted RNA was quantified using a BioTek Take3 plate using
Microspots setting on the Gen5 nucleic acid application, and RNA was diluted in nuclease-free
water to a concentration of 50 ng/µL. The iTaq Universal SYBR Green One-Step Kit (BioRad)
was used to perform the quantitative PCR. A reaction volume of 10 µL was used. The reaction
mix consisted of 5 µL iTaq SYBR Green One-Step mix, 0.125 µL iScript Reverse Transcriptase,
0.5 µL of primer mix consisting of both forward and reverse primers, 2.375 µL nuclease-free
water, and 2 uL 50 ng/µL RNA. The recommended thermal cycler protocol that accompanies the
kit was used. Three primers were included in these experiments: P-gp (ABCB1), BCRP
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(ABCG2), and ß-actin (ACTB) for reference (all from Bio-Rad). The fold change was calculated
using the following equation:
𝐹𝑜𝑙𝑑 𝐶ℎ𝑎𝑛𝑔𝑒 (𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑) =

𝐸𝑡𝑎𝑟𝑔𝑒𝑡 ∆𝐶𝑇𝑡𝑎𝑟𝑔𝑒𝑡
𝐸𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 ∆𝐶𝑇𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒

where E is the pre-determined reaction efficiency and ΔCT values were determined from PCR
experiments. The Bio-Rad CFX Touch Real Time PCR detection system was used. Either white
tube strips with clear lids or plates with clear seals were used.

2.2: Western Blot
Also as part of the characterization studies of the putative BCRP overexpressing cell
lines, Western blot analyses were used to qualitatively determine the level of protein expression
of ABC transporters in the S1 (parental human colon cancer), S1M1-80 (MDR version of S1),
H460 (parental human non-small cell lung cancer), MX20 (MDR version of H460), MCF7
(human parental breast cancer), and M100 (MDR version of MCF7) cell lines. Whole cell lysates
were prepared using at least two million cells from each cell line. Cells were lysed in 500 μL of
SDS buffer (125 mM Tris HCl pH 6.8, 20% v/v glycerol, 4% w/v SDS and 2% v/v βmercaptoethanol) containing 5 μL of protease inhibitor cocktail (P8340, Sigma). The lysates
were filtered through a spin column (QIAprep®) by centrifugation at 5000 rpm for 5 minutes in a
microcentrifuge and used for Western blot analysis. The total protein concentration for each
lysate sample was first quantified using a modified Lowry protein assay (Peterson, 1977). Before
beginning Western blot procedures, the lysate proteins were incubated in a 37°C water bath for
10 minutes. 30 µg of each protein lysate was then loaded into the gel and resolved by denaturing
SDS-PAGE (8% separating gel with 5% stacking gel, 1.5 mm, 10 well) for 100 minutes at 110 V
and subsequently transferred to a PVDF membrane (BioRad) using a Mini Transblot cell
10

(BioRad) for 70 minutes at 110 V. The transfer buffer contained 192 mM glycine, 25 mM Tris,
and 10% methanol with a pH of 8.3. The membrane was blocked overnight at 4 °C with 4%
powdered skimmed milk in TBS-T (12 mM Tris–HCl pH 7.5, 0.5 M NaCl, 0.05% Tween 20).
Washed membranes were incubated overnight at 4 °C with the P-gp mouse monoclonal antibody
C219 (Enzo Life Sciences, NY), the BCRP-specific monoclonal antibody B1 (Santa Cruz
Biotechnology, CA), or the β-actin monoclonal antibody C4 (Santa Cruz Biotechnology, CA),
diluted to 1:125 for BCRP and 1:500 for P-gp and ß-actin in TBS-T and 4% powdered skimmed
milk. Washed membranes were subsequently incubated for 1 hour at room temperature with
alkaline horseradish peroxidase-conjugated goat anti-mouse secondary antibody sc-2005 (Santa
Cruz Biotechnology, CA) diluted to 1:1000 in TBS-T containing 4% milk powder. Membranes
were washed in TBS-T and P-gp, BCRP, or β-actin were visualized using enhanced
chemiluminescence detection (ECL kit, Thermo Scientific, IL) with the BioRad ChemiDoc
system.

2.3: Cell Culture
2.3.1: Cell Lines and Culture
The MCF7 cell line (human adenocarcinoma breast cancer) was purchased from ATCC,
VA. The MDR cell line MCF7-M100 was established in our lab by treating the MCF7 parental
cell line with sub-lethal concentrations of mitoxantrone as previously described (Nakagawa et
al., 1992 and Nanayakkara et al., 2018). M100 cells were maintained with 100 nM mitoxantrone
for positive selective pressure. S1 (human colon cancer), S1M1-80 (multidrug resistant version
of parental S1), H460 (human lung non-small cell carcinoma), and MX20 (multidrug resistant
version of parental H460) cells were generously shared by Dr. Amit Tiwari’s lab at the
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University of Toledo. S1M1-80 and MX20 cells were maintained under 80 nM and 1 nM
mitoxantrone respectively. All cancer cell lines were grown in complete media consisting of
RPMI-1640 with L-glutamine, 10% fetal bovine serum (FBS, Corning), 100 U/mL penicillin
(Corning), and 100 µg/mL streptomycin (Corning).
The immortalized human cerebral microvascular endothelial cell line hCMEC/D3
(Weksler et al., 2005) was a generous gift from Dr. Ashlee Moses (Oregon Health and Science
University, Oregon, USA). These cells were maintained in EBM-2 medium (Lonza, MD)
supplemented with EGM-2 MV BulletKit Medium (Lonza, MD), 1% Chemically defined lipid
concentrate (Gibco, USA), 5% fetal FBS (Corning, NY), 100 U/mL penicillin and 100 μg/mL
streptomycin. All growth surfaces for the hCMEC/d3 cells were treated with 0.1 mg/mL collagen
I (Corning rat-tail high concentration collagen) in 0.02 N acetic acid for 10 minutes, then rinsed
with PBS before adding cells and media.
All cells were maintained in a humidified incubator at 37°C and 5% CO2.

2.3.2: Cell Culture Assays with Cancer Cells
The MTT cell viability assay is a colorimetric assay that utilizes the reduction of the
yellow, water soluble 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) to
water insoluble blue formazan crystals by cellular reductase activities in living cells (Mosmann,
1983). MTT was purchased from MP Biomedicals (Santa Ana, CA). The S1 and S1M1-80, H460
and MX20, and MCF7 and M100 cells were plated at 3,000, 6,000, and 5,000 cells per well,
respectively, in 96 well cell culture sterile plates. Cells were allowed to attach for 24 hours.
Experimental and control compounds as well as chemotherapeutics were then added. It was
necessary to determine whether 48 or 72 hours was the optimal drug incubation period. Using the

12

above-mentioned cell viability assays, it was concluded that a 72 hour drug incubation provided
the most clear results, and this incubation time was used for all cell viability assays involving the
six mentioned cancer cell lines. The media was then aspirated and 80 μL fresh complete media
was added to each experimental well. MTT was immediately added to the wells (20 μL/well of
5 mg/mL MTT in PBS) and allowed to incubate for 4 hours. The supernatant was then carefully
removed so as not to disturb the crystals, and the formazan crystals were solubilized in 100
μL/well pure DMSO by shaking the plates for 10 minutes at 500 rpm on an orbital plate shaker.
The absorbance was measured at 570 nm using a Bio‐Tek Eon plate reader (Bio‐Tek, Winooski,
VT). The absorbance values were assumed to directly correlate with the number of metabolically
active cells. The percent viability was calculated using the following equation:
% 𝐶𝑒𝑙𝑙 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = 100 ∗

𝐴𝑏𝑠570 𝑛𝑚 𝑡𝑒𝑠𝑡 𝑤𝑒𝑙𝑙 𝑎𝑣𝑔
𝐴𝑏𝑠570 𝑛𝑚 𝐷𝑀𝑆𝑂 − 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑤𝑒𝑙𝑙 𝑎𝑣𝑔

GraphPad Prism (San Diego, CA) was used for cell viability analysis. A nonlinear
regression curve fit was used in the experiments with multiple concentrations of mitoxantrone,
specifically the “log(inhibitor) vs. response – variable slope (four parameters)” analysis. For
experiments with one mitoxantrone concentration (bar graphs), one-way ANOVA analysis was
used to determine statistical significance. Specifically, Sidak’s multiple comparison test was
used to compare compound versus compound with mitoxantrone, and Dunnett’s multiple
comparison test was used to compare the mitoxantrone only control to mitoxantrone and
compound samples.

2.3.3: Cell Culture Assays with Blood-Brain Barrier Cells
In order to test the efficacy of using our P-gp modulating compounds at the blood-brain
barrier (BBB), substrate accumulation assays were used to determine the level of accumulation
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of fluorescent P-gp substrates when P-gp was inhibited in the BBB cells. For these substrate
accumulation assays, hCMEC/d3 (human cerebral microvascular endothelial) cells were seeded
at 5,000 cells per well in 96 well plates and allowed to grow until fully confluent (4 to 5 days).
Cells were treated with indicated compounds for 3 hours. After this incubation, cells were treated
with one of the following P-gp fluorescent substrates: rhodamine 123 (Life Technologies, OR),
calcein-AM (Life Technologies, OR), or Hoechst 33342 (Life Technologies, OR). For the
substrate accumulation assay with Rhodamine 123 cells were treated with 2.5 µM Rhodamine
123 for 90 minutes. Media was aspirated and cells were washed three times with 200 µL PBS.
Cells were then lysed in 100 µL 0.8% SDS and 0.8% Triton X100 in PBS. 25 µM verapamil, a
P-gp substrate, was used as a positive control and vehicle controls were treated with 0.05%
DMSO. The fluorescence was measured at an excitation of 488 nm and emission at 575 nm, both
with 20 nm gate using a Cytation 5 (BioTek) plate reader. For the substrate accumulation assay
with Hoechst 33342, the media was replaced with phenol red-free media after cells reached
confluency and before adding compounds. After the initial compound incubation, cells were
treated with 1 µg/mL of Hoechst 33342. Fluorescence was measured at excitation 361 nm and
emission 487 nm, both with 20 nm gate, on the Cytation 5. For the substrate accumulation assay
with calcein-AM, the media was replaced with phenol red-free media after cells reached
confluency and before adding compounds. After the initial compound incubation, cells were
treated with 1 µg/mL calcein-AM. Fluorescence was measured at excitation 485 nm and
emission 535 nm, both with 20 nm gate, on the Cytation 5. Fold accumulation was calculated
and normalized to vehicle treated cells. Successful P-gp inhibition is depicted when cells treated
with our P-gp modulators have increased intracellular fluorescence compared to vehicle treated
cells.
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2.3.4: Chemicals and Compounds Used Throughout Experiments
Mitoxantrone (Santa Cruz Biotechnology, CA) was used as part of the drug treatment in
MTT viability assays as well as during passaging MX20, S1M1-80, and M100 cells to maintain
positive selective pressure on these multidrug resistant cell lines. DMSO was used a vehicle for
drugs in the MTT viability and compound accumulation assays. The fumitremorgin C analogue
Ko143 (Sigma), a reported BCRP inhibitor (Allen et al., 2002), was used as a positive control.
For one of the MTT viability experiments with MX20 cells, tariquidar (MedKoo Biosciences,
Chapel Hill, NC) was used to inhibit any P-gp present (Bates & Fox, 2014 and Weidner et al.,
2016).
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CHAPTER 3
RESULTS

3.1: Characterization of BCRP Overexpressing Cell Lines
3.1.1: Quantitative Real-Time Polymerase Chain Reaction
Before commencing studies to reverse multidrug resistance (MDR) mediated by the
breast cancer resistance protein, BCRP, through the use of novel BCRP inhibitors, it was
necessary to characterize the MDR cell lines used in the study to confirm that the cells do, in
fact, overexpress BCRP. Ideally, the MDR cell lines would only overexpress BCRP and not any
of the other ABC transporters so that potential inhibitors could be tested for specificity for
BCRP. The cell lines characterized here include MCF7 (human breast cancer), M100 (multidrug
resistant version of MCF7), S1 (human colon cancer), S1M1-80 (multidrug resistant version of
parental S1), H460 (human lung non-small cell carcinoma), and MX20 (multidrug resistant
version of parental H460). The multidrug resistant M100 cells used in this study were obtained
by exposing MCF7 cells to increasing concentrations of mitoxantrone until the cells became
resistant to 100 nM mitoxantrone (Nanayakkara et al., 2018). This was accomplished after 60
cell passages. Previous work with these cells by others in the lab indicated that after several
passages (up to and over cell passage 100) at the 100 nM mitoxantrone concentration, the M100
cells were dying at an unprecedentedly slow rate, responded differently to drug treatment, and
had undergone slight morphological changes. It was hypothesized that during the multiple
passages at high concentrations of chemotherapeutics, other resistance mechanisms may have
16

established in the cells. To have a potentially truer reliance on BCRP as a sole resistance
mechanism, M100 cells from passage 60 (the earliest passage resistant cells available) were used
in the experiments in this study and evaluated for BCRP overexpression. During the experiments
presented here, the cells did not undergo more than a total of 10 additional passages.
In order to characterize the levels of expression of ABC transporters in the putative
BCRP overexpressing cell lines, quantitative real-time polymerase chain reaction (qRT-PCR)
was performed as shown in Figure 3.1. Actin beta (ACTB) was used as a reference gene. Results
suggested that MX20 cells overexpressed BCRP almost 20-fold and P-gp almost 15-fold
compared to the parental H460 (Figure 3.1A). qRT-PCR results also indicated that M100 cells
overexpressed BCRP about 40-fold compared to parental MCF7 with no overexpression of P-gp
(Figure 3.1B), and S1M1-80 cells overexpressed BCRP more than 15,000-fold compared to
parental S1 with no overexpression of P-gp (Figure 3.1C). In all three MDR cell lines, no
significant expression of MRP1, another ABC transporter implicated in MDR (Chen and Tiwari,
2011) was observed. The results therefore indicated BCRP overexpression in each MDR cell
line, as expected, at least on the mRNA level. However, the results also suggested that MX20
overexpressed P-gp and may therefore not be a very good model to use for assessing BCRP
specific inhibition.
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B

C

Figure 3.1: qRT-PCR of BCRP Overexpressing Cancer Cell Lines
The RNA expression levels of three ABC transporters (BCRP, P-gp, and MRP1) were
measured in three MDR cancer lines and compared to the level of RNA expression of those
same proteins in their respective parental cell lines. Results are expressed in fold change
normalized to the RNA expression in parental lines as well as ACTB expression. Parental
H460 and MDR MX20 lines are shown in (A), parental MCF7 and MDR M100 are shown in
(B), and parental S1 and MDR S1M1-80 are shown in (C). Errors bars represent pooled SD
with n=2 for each primer and RNA set.
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3.1.2: Western Blot Analysis
While the cell lines had been characterized on their RNA expression level using qRTPCR, it was also important to assess the level of protein expression of the different multidrug
resistance proteins in the M100 breast cancer, S1M1-80 colon cancer, and MX20 non-small cell
lung cancer cells as well as their respective parental cell lines.

Figure 3.2: Western Blot of BCRP Overexpressing Cell Lines.
Western blot analyses were performed with six cell lines including MCF7, M100, S1, S1M180, H460, and MX20 using anti-P-gp, anti-BCRP, and anti-ACTB antibodies.
The Western blot analysis (Figure 3.2) confirmed overexpression of BCRP in all three
MDR cell lines, as expected from the qRT-PCR results. The blot also showed a visible band for
P-gp in both the parental H460 and MDR MX20 lines. It is of note that qRT-PCR results
suggested the BCRP and P-gp RNA expression levels in the MX20 line were about the same.
However, Western blot analysis indicated that on the protein level, BCRP was expressed to a
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much greater extent than P-gp. Thus it can be assumed that the MX20 cells express both BCRP
and P-gp proteins, though BCRP is expressed to a much greater extent than P-gp.

3.1.3: MDR In Vitro Profile of Cancer Cells
In order to confirm that our cell culture models (i.e., the MDR BCRP overexpressing cell
lines confirmed as such via qRT-PCR and Western blotting) were functional for our purpose of
testing novel compounds for MDR reversal via BCRP inhibition, it was first necessary to test the
cell lines for their MDR phenotype. Cell viability assays were performed using a gradient of
mitoxantrone (MNT) concentrations. Cells were treated with either MNT alone or MNT and
Ko143, a known BCRP inhibitor (Allen et al., 2002). The presence of a BCRP inhibitor should
cause re-sensitization of the MDR cells to chemotherapeutics, as observed by a shift in the cell
viability curve towards the lower concentrations of mitoxantrone.
First, it was necessary to test which drug incubation period worked best with our model,
48 or 72 hours (Figures 3.3-3.5), or in other words, how long cells needed to be incubated with
the chemotherapeutic for cell death to occur. Unexpectedly, when S1M1-80 and MX20 cells
were treated with Ko143, they almost always showed an increase in cell viability compared to
control cells, regardless of incubation time. This occurred in other experiments as well (Figures
3.9-3.10). The concentration of DMSO was 0.5% for every sample, so the reason this increase in
cell viability with Ko143 treated cells was observed is unknown. It would be useful to explore
this in future studies. It is also important to note that the most likely reason the “MNT only”
treated S1M1-80 cells with 48 hour incubation depicted in Figure 3.4A seem to have a linear
curve is due to the large error bars, particularly at the lower MNT concentrations. For all three
BCRP overexpressing cell lines, 72 hours was deemed the better incubation time as observed
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from the narrowing of noise between replicates and a more pronounced sensitivity of the cells to
chemotherapeutic in the presence of the BCRP inhibitor, as observed in the shift between curves
for “MNT only” control cells and “MNT treated” cells in the presence of MNT and Ko143.
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B

Figure 3.3: MDR in Vitro Profile of the BCRP Overexpressing M100 Cell Line.
M100 cells were treated with different concentrations of MNT only (black circles) or MNT and 1
µM Ko143 (purple squares). After 48 (A) or 72 (B) hours of drug incubation, cell viability was
measured using the MTT assay described in methods. Each graph presents the average ± SD,
n=8 from two individual experiments.
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B

Figure 3.4: MDR in Vitro Profile of the BCRP Overexpressing S1M1-80 Cell Line.
S1M1-80 cells were treated with different concentrations of MNT only (black circles) or MNT
and 1 µM Ko143 (purple squares). After 48 (A) or 72 (B) hours of drug incubation, cell viability
was measured using the MTT assay described in methods. Each graph presents the average ± SD,
n=8 from two individual experiments.
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Figure 3.5: MDR in Vitro Profile of the BCRP Overexpressing MX20 Cell Line.
MX20 cells were treated with different concentrations of MNT only (black circles) or MNT and
1 µM Ko143 (purple squares). After 48 (A) or 72 (B) hours of drug incubation, cell viability was
measured using the MTT assay described in methods. Each graph presents the average ± SD, n=8
from two individual experiments.
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3.2.1: Analysis of “Top Hits” Compounds SMU-50, 53, 70, 71, 83, 103, 117
One way to assess the effectiveness of potential inhibitors of multidrug resistance
proteins is to evaluate the ability of the proteins to export specific transport substrates. After the
MDR cell lines available to us were confirmed as BCRP overexpressing and the conditions for
the cell viability assays had been optimized, we evaluated an in-house library of small, drug-like
compounds for their effects on MDR reversal and BCRP inhibition. The in-house compound
library consisted of commercially available small molecules that we had discovered through
massive parallel in silico screens against ABC transporters, similar to studies described in
(Brewer et al., 2014; McCormick et al., unpublished). A substrate accumulation assay previously
performed in the lab (Nanayakkara, 2019) used the BCRP substrate, Hoechst 33342
(Scharenberg et al., 2002) to identify which of our hit compounds caused substrate accumulation
when the BCRP overexpressing M100 cells were treated with the potential BCRP inhibitors.
Hoechst 33342 is a chemical dye that becomes fluorescent upon binding to DNA (Bircsak et al.,
2013). When ABC transporter function is modulated, such as by the addition of BCRP inhibitors,
their efflux function is impaired, and Hoechst 33342 accumulates inside the cells. The
fluorescence intensity of the accumulated Hoechst 33342 can then be quantitatively measured
and compared between compounds. Using these assays, Nanayakkara (2019), identified several
compounds as “Top Hits” for BCRP inhibition because they resulted in an estimated 4-fold
increase or more in fluorescent intensity and Hoechst 33342 accumulation as compared to the
DMSO vehicle-treated controls. These “Top Hit” compounds include compounds 50, 53, 70, 71,
83, 103, and 117.
Nanayakkara (2019) also previously established an assay in our lab where cells were
treated with or without mitoxantrone (MNT), similar to the experiments shown in Figures 3.3-
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3.5, to establish whether the compounds reversed MDR in the BCRP overexpressing M100 cell
line. For those initial assays, M100 cells were used that had been passaged in the presence of 100
nM MNT 90 -100 times. These assays revealed that significant cell death of these M100 cells
was not observed even after long time exposure to very high amounts of MNT. We hypothesized
that upon extended passages in the presence of MNT, the cells may have accumulated additional
mutations that would interfere with the established BCRP overexpression phenotype, as had been
observed by others as well (Hughes et al., 2018). To assess this hypothesis, M100 cells were
used that had been passaged significantly fewer times, starting at passage number 60, the lowest
passage number that resulted in resistance to 100 nM mitoxantrone. These cells were used for 10
passages or less during each experimental set described here, therefore potentially accumulating
fewer additional mutations. This “lower passage” M100 cell line as well as the two additional
BCRP overexpressing cell lines S1M1-80 and MX20 were used to assess the previously
established “Top Hit” compounds for their effectiveness in reversing chemotherapy resistance to
MNT.
In these assays, the various cell lines were incubated with either 1 μM Ko143 or 10 μM
experimental compound with or without MNT for 72 hours. The remaining cell viability was
assessed using the MTT cell viability assay (Mosmann, 1983). Ko143 was used as a positive
control for a BCRP inhibitor, and DMSO was used as the vehicle control. The MNT only control
was included in order to determine cell viability of the cancer cells in the presence of
chemotherapeutic alone and to deduce potential re-sensitization of the MDR cancers to MNT in
the presence of the experimental compounds.
For the breast cancer M100 cells, compounds 70, 71, 83, and 117 displayed significantly
lower viability when treated with both the compound and MNT compared to compound alone
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(Figure 3.6 and Table 3.1), thus suggesting that these compounds reversed MDR in this cell line
while not being overly toxic by themselves. When compared to MNT only treated cells, all tested
compounds except 117 showed significantly reduced cell viability (Table 3.1). This indicates
that these compounds seem to restore M100 cells’ sensitivity to mitoxantrone.

Figure 3.6: Top Hits in M100 Cell Line.
M100 were treated with 10 µM indicated compound or 1 µM Ko143 alone (gray bars) or
compound with MNT (light blue bars). The concentration of MNT was 200 nM. After 72 hours
of drug incubation, cell viability was measured using the MTT assay described in methods.
Each graph presents the average ± SD, n=8 from two individual experiments. Significance
represents compound only compared to compound with MNT. NS=not significant (P > 0.05),
*P ≤ 0.05, **P≤ 0.01, ***P≤ 0.001, ****P ≤ 0.0001
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Treatment
MNT Only
Ko143+MNT
50+MNT
53+MNT
70+MNT
71+MNT
83+MNT
103+MNT
117+MNT

% Cell Viability

% Cell Viability
(MNT Only – Treatment)

80.750
43.625
54.625
60.000
58.375
33.875
42.875
57.750
72.125

37.125
26.125
20.750
22.375
46.875
37.875
23.000
8.625

Significance
****
****
***
***
****
****
***
NS

Table 3.1: Top Hits in M100 Cell Line.
M100 cells were treated with 10 µM indicated compound or 1 µM Ko143 and 200 nM MNT.
After 72 hours of drug incubation, cell viability was measured using the MTT assay described
in methods. Each graph presents the average, n=8 from two individual experiments.
Significance represents compound and MNT compared to MNT only. NS=not significant (P >
0.05), *P ≤ 0.05, **P≤ 0.01, ***P≤ 0.001, ****P ≤ 0.0001

In the colon cancer S1M1-80 cells (Figure 3.7), only the control Ko143 showed
significant difference in cell viability between compound only and compound with MNT treated
cells. However, there was a statistically significant difference in cell viability when experimental
compounds were incubated together with MNT compared to MNT alone for compounds 70, 103,
and 117 (Table 3.2). These data suggest that the Top Hit compounds might not significantly
cause MDR reversal in the S1M1-80 cells, but compounds 70, 103, and 117 seem to restore
some sensitivity to MNT in these cells. Compound 103 displayed strong cytotoxicity when added
to the cells by itself without any chemotherapeutic.
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Figure 3.7: Top Hits in S1M1-80 Cell Line.
M100 were treated with 10 µM indicated compound or 1 µM Ko143 alone (gray bars) or
compound with MNT (light blue bars). The concentration of MNT was 100 nM. After 72 hours
of drug incubation, cell viability was measured using the MTT assay described in methods.
Each graph presents the average ± SD, n=8 from two individual experiments. Significance
represents compound only compared to compound with MNT. NS=not significant (P > 0.05),
*P ≤ 0.05, **P≤ 0.01, ***P≤ 0.001, ****P ≤ 0.0001
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Treatment
MNT Only
Ko143+MNT
50+MNT
53+MNT
70+MNT
71+MNT
83+MNT
103+MNT
117+MNT

% Cell Viability

% Cell Viability
(MNT Only – Treatment)

102.250
75.000
83.125
99.375
54.375
66.625
92.875
18.625
50.750

27.250
19.125
2.875
47.875
35.625
9.375
83.625
51.500

Significance
NS
NS
NS
*
NS
NS
****
*

Table 3.2: Top Hits in S1M1-80 Cell Line.
S1M1-80 cells were treated with 10 µM indicated compound or 1 µM Ko143 and 100 nM
MNT. After 72 hours of drug incubation, cell viability was measured using the MTT assay
described in methods. Each graph presents the average, n=8 from two individual experiments.
Significance represents compound and MNT compared to MNT only. NS=not significant (P >
0.05), *P ≤ 0.05, **P≤ 0.01, ***P≤ 0.001, ****P ≤ 0.0001

In the lung cancer MX20 cells (Figure 3.8), compounds 50 and 70 showed statistically
significant cell viability differences between compound only and compound with MNT treated
cells, thus suggesting that these compounds cause MDR reversal in these cells. None of the
tested compounds, including the Ko143 control, displayed strongly reduced cell viability of
compound with MNT compared to MNT only (Table 3.3), indicating that these compounds may
not re-sensitize these cells to MNT. Considering these results, and taking into account that P-gp
seemed to be overexpressed in the MX20 cells as well, it seemed interesting to consider how the
MX20 cells would respond to the Top Hit compounds if P-gp was inhibited in these cells. This
idea is pursued in results reported in section 3.2.2.
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Figure 3.8: Top Hits in MX20 Cell Line.
M100 were treated with 10 µM indicated compound or 1 µM Ko143 alone (gray bars) or
compound with MNT (light blue bars). The concentration of MNT was 2 nM. After 72 hours of
drug incubation, cell viability was measured using the MTT assay described in methods. Each
graph presents the average ± SD, n=8 from two individual experiments. Significance represents
compound only compared to compound with MNT. NS=not significant (P > 0.05), *P ≤ 0.05,
**P≤ 0.01, ***P≤ 0.001, ****P ≤ 0.0001
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Treatment
MNT Only
Ko143+MNT
50+MNT
53+MNT
70+MNT
71+MNT
83+MNT
103+MNT
117+MNT

% Cell Viability

% Cell Viability
(MNT Only – Treatment)

71.625
64.250
57.375
63.750
56.375
56.250
62.000
44.375
54.375

7.375
14.250
7.875
15.250
15.375
9.625
27.250
17.250

Significance
NS
NS
NS
NS
NS
NS
NS
NS

Table 3.3: Top Hits in MX20 Cell Line.
MX20 cells were treated with 10 µM indicated compound or 1 µM Ko143 and 2 nM MNT.
After 72 hours of drug incubation, cell viability was measured using the MTT assay described
in methods. Each graph presents the average, n=8 from two individual experiments.
Significance represents compound and MNT compared to MNT only. NS=not significant (P >
0.05), *P ≤ 0.05, **P≤ 0.01, ***P≤ 0.001, ****P ≤ 0.0001
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Another way to analyze how well the experimental compounds reversed MDR was to
assess how MDR cells responded to different concentrations of MNT, similar to the experiments
described in Figures 3.3 – 3.5. The BCRP overexpressing cell lines S1M1-80 and MX20 were
treated with different MNT concentrations in the presence of 10 µM of experimental compounds
or 1 µM Ko143. The cell viability curves of cells that were treated with MNT in the presence of
experimental compounds were compared to MNT only curves for both the parental and MDR
cells as well as the Ko143 control. If the curve of cells treated with compound was shifted to the
left, it suggested that the cells had become more sensitized to MNT, as observed by comparing
the positive control Ko143 to MNT only treated cells.
For the S1M1-80 cells (Figure 3.9), compounds 50 and 117 only slightly sensitized the
cells, while the curve for compound 53 was similar to the curve for Ko143 treated cells.
Compounds 70 and 83 showed slight initial cytotoxicity, and their curves were not significantly
shifted in any way. Compound 103 showed great cytotoxic effects. While 71 was originally
included in the list of Top Hits, it was not included in these assays due to issues with solubility
and cytotoxicity.
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Figure 3.9: Top Hits with Multiple MNT Concentrations in S1M1-80 Cells.
S1M1-80 cells were treated with multiple MNT concentrations and 10 µM indicated
compound or 1 µM Ko143. Each MDR cell line’s parental cell line is also included on each
graph. After 72 hours of drug incubation, cell viability was measured using the MTT assay
described in methods. Each graph presents the average ± SD, n=8 from two individual
experiments.

For the MX20 cells (Figure 3.10), all compounds sensitized cells to MNT but only
compounds 50 and 70 curves were shifted further to the left than that of Ko143. Compound 103
showed a great deal of cytotoxicity, while compounds 50 and 70 displayed slight cytotoxicity.
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Figure 3.10: Top Hits with Multiple MNT Concentrations in MX20 Cells.
MX20 cells were treated with multiple MNT concentrations and 10 µM indicated compound
or 1 µM Ko143. Each MDR cell line’s parental cell line is also included on each graph. After
72 hours of drug incubation, cell viability was measured using the MTT assay described in
methods. Each graph presents the average ± SD, n=8 from two individual experiments.

3.2.2: Assessing Top Hits in MX20 Cells in the Presence of the Strong P-gp Inhibitor
Tariquidar
The results from the qPCR and Western blots, along with the unexpected results from the
Top Hit cell viability assay, led to further investigation with the MX20 cell line. The qPCR and
Western results showed that while BCRP was very overexpressed in these cells, P-gp was also
expressed to some degree. To evaluate whether the expression of P-gp in these cells was
affecting some of the resistance reversal in the presence of the BCRP inhibitory compounds,
cells were treated with compound and MNT or compound, MNT, and tariquidar (TQR). TQR is
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a known P-gp-specific inhibitor (Bates & Fox, 2014 and Weidner et al., 2016). If P-gp could be
effectively inhibited, then the effectivity of the novel compounds on just BCRP in the MX20
could be more specifically investigated. The control, Ko143, as well as compounds 53, 83, and
117 showed significant reduction in cell viability for the cells treated with MNT, compounds,
and TQR compared to those treated with compound and MNT (Figure 3.11), suggesting that
when P-gp is inhibited, these compounds cause reversal of MDR in the MX20 cells. This also
supports the previous evidence that both P-gp and BCRP are expressed and may both contribute
to MDR in this cell line.
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Figure 3.11: Effect of TQR on Compound MDR Reversal in MX20 Cells.
MX20 cells were treated with 10 µM indicated compound or 1 µM Ko143 and 2 nM MNT
without (blue) or with (brown) 500 nM TQR. After 72 hours of drug incubation, cell viability
was measured using the MTT assay described in methods. Each graph presents the average ± SD,
n=8 from two individual experiments. Significance represents compound with MNT compared to
compound with MNT and TQR. NS=not significant (P > 0.05), *P ≤ 0.05, **P≤ 0.01, ***P≤
0.001, ****P ≤ 0.0001
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3.3: Analysis of “Almost Hits” Compounds SMU-57, 79, 96, 120, 124
In the mentioned Hoechst screening of potential BCRP inhibitors (Nanayakkara 2019),
there were also a few compounds that were very close to the cut-off for being a Top Hit,
meaning they had slightly below 4-fold increased intracellular substrate accumulation. These
compounds include 57, 79, 96, 120, and 124, and they are referred to hereafter as “Almost Hits.”
Since the Top Hits compounds displayed varying results in the different cell lines, these “Almost
Hits” compounds were also tested in the three BCRP overexpressing cell lines to determine if
perhaps any of the previously disregarded compounds from the Hoechst screen might actually be
useful in future BCRP inhibitor studies.
In the breast cancer M100 cells (Figure 3.12), compounds 57, 79, 96, 120, and 124 all
suggested significant MDR reversal, as indicated by comparing compound versus compound
with MNT treated cells, with seemingly no cytotoxic effects of the compounds themselves.
When compared to the MNT only control (Table 3.4), compound 79 and 120 showed an obvious
and significant reduction in cell viability when cells were treated with compound and MNT. This
suggests that these compounds seem to significantly re-sensitize the M100 cells to MNT.
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Figure 3.12: Almost Hits in M100 Cell Line.
M100 cells were treated with 10 µM indicated compound or 1 µM Ko143 alone (gray bars) or
compound with MNT (light blue bars). The concentration of MNT was 200 nM. After 72
hours of drug incubation, cell viability was measured using the MTT assay described in
methods. Each graph presents the average ± SD, n=8 from two individual experiments.
Significance represents compound only compared to compound with MNT. NS=not
significant (P > 0.05), *P ≤ 0.05, **P≤ 0.01, ***P≤ 0.001, ****P ≤ 0.0001
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Treatment
MNT Only
Ko143+MNT
57+MNT
79+MNT
96+MNT
120+MNT
124+MNT

% Cell Viability

% Cell Viability
(MNT Only – Treatment)

75.375
33.625
61.500
33.125
68.750
40.250
91.625

41.750
13.875
42.250
6.625
35.125
-16.250

Significance
****
NS
***
NS
****
NS

Table 3.4: Almost Hits in M100 Cell Line.
M100 cells were treated with 10 µM indicated compound or 1 µM Ko143 and 200 nM MNT.
After 72 hours of drug incubation, cell viability was measured using the MTT assay described
in methods. Each graph presents the average, n=8 from two individual experiments.
Significance represents compound and MNT compared to MNT only. NS=not significant (P >
0.05), *P ≤ 0.05, **P≤ 0.01, ***P≤ 0.001, ****P ≤ 0.0001

In the colon cancer S1M1-80 cells (Figure 3.13), no compounds besides the Ko143
control displayed any significant MDR reversal. This is suggested by the lack of strong change in
cell viability of compound versus compound and MNT treated cells. Compound 120 showed
cytotoxic effects to this cell line. However, compounds 79 and 120 exhibited statistically
significantly reduced cell viability in compound and MNT treated cells compared to MNT only
treated cells (Table 3.5); however, the effect seen in compound 120 treated cells is most likely
due to the cytotoxicity of the compound. Thus, 79 seems to be the only compound that, at least to
a smaller degree, restores MNT sensitivity in the M100 cells.
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Figure 3.13: Almost Hits in S1M1-80 Cell Line.
S1M1-80 cells were treated with 10 µM indicated compound or 1 µM Ko143 alone (gray
bars) or compound with MNT (light blue bars). The concentration of MNT was 100 nM.
After 72 hours of drug incubation, cell viability was measured using the MTT assay described
in methods. Each graph presents the average ± SD, n=8 from two individual experiments.
Significance represents compound only compared to compound with MNT. NS=not
significant (P > 0.05), *P ≤ 0.05, **P≤ 0.01, ***P≤ 0.001, ****P ≤ 0.0001
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Treatment
MNT Only
Ko143+MNT
57+MNT
79+MNT
96+MNT
120+MNT
124+MNT

% Cell Viability

% Cell Viability
(MNT Only – Treatment)

74.500
38.125
65.625
50.125
67.875
29.125
76.750

38.375
9.875
25.375
6.625
45.375
-2.25

Significance
****
NS
***
NS
****
NS

Table 3.5: Almost Hits in S1M1-80 Cell Line.
S1M1-80 cells were treated with 10 µM indicated compound or 1 µM Ko143 and 100 nM
MNT. After 72 hours of drug incubation, cell viability was measured using the MTT assay
described in methods. Each graph presents the average, n=8 from two individual experiments.
Significance represents compound and MNT compared to MNT only. NS=not significant (P >
0.05), *P ≤ 0.05, **P≤ 0.01, ***P≤ 0.001, ****P ≤ 0.0001

In the non-small cell lung cancer MX20 cells (Figure 3.14), none of the “Almost Hits”
compounds (57, 79, 96, 120, and 124) displayed statistically significant reduced viability in cells
treated with compound and MNT compared to compound only treated cells, suggesting that these
compounds do not help overcome MDR in these cells. However, only compound 57 showed a
marked and significant cell viability reduction in cells treated with compound and MNT
compared to MNT only treated cells, suggesting that 57 restores MNT sensitivity in the MX20
cells (Table 3.6).
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Figure 3.14: Almost Hits in MX20 Cell Line.
MX20 cells were treated with 10 µM indicated compound or 1 µM Ko143 alone (gray bars)
or compound with MNT (light blue bars). The concentration of MNT was 2 nM. After 72
hours of drug incubation, cell viability was measured using the MTT assay described in
methods. Each graph presents the average ± SD, n=8 from two individual experiments.
Significance represents compound only compared to compound with MNT. NS=not
significant (P > 0.05), *P ≤ 0.05, **P≤ 0.01, ***P≤ 0.001, ****P ≤ 0.0001
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Treatment
MNT Only
Ko143+MNT
57+MNT
79+MNT
96+MNT
120+MNT
124+MNT

% Cell Viability

% Cell Viability
(MNT Only – Treatment)

81.250
80.875
44.375
66.125
85.000
73.250
83.250

0.375
36.875
15.125
-3.750
8.000
-2.000

Significance
NS
**
NS
NS
NS
NS

Table 3.6: Almost Hits in MX20 Cell Line.
MX20 cells were treated with 10 µM indicated compound or 1 µM Ko143 and 2 nM MNT.
After 72 hours of drug incubation, cell viability was measured using the MTT assay described
in methods. Each graph presents the average, n=8 from two individual experiments.
Significance represents compound and MNT compared to MNT only. NS=not significant (P >
0.05), *P ≤ 0.05, **P≤ 0.01, ***P≤ 0.001, ****P ≤ 0.0001
3.4: Assessing P-gp Modulators for Potential Use at the Blood-Brain Barrier
As previously mentioned, the use of ABC transporter inhibitors could also potentially be
applied to modulate transport activity of cells of the blood-brain barrier (BBB). To understand
whether compounds discovered in our lab might affect P-gp or BCRP in the BBB, substrate
accumulation assays were performed using the hCMEC/d3 cerebral microvascular endothelial
cell line. The compounds tested in this work were three structural variants of a compound,
compound 29, that was earlier discovered by our lab (Brewer et al., 2014) to be a strong inhibitor
of P-gp and reverse MDR in several cancer cells in culture (Follit et al., 2015 and Nanayakkara
et al., 2018). The variants of 29, compounds 231, 238, and 255 are previously described (Wise et
al., 2019). Verapamil (VER), a known P-gp inhibitor, was used as a positive control, and DMSO
was used as the vehicle. Three fluorescent substrates were used: Hoechst 33342 (Hoechst, a
substrate for P-gp and BCRP), Rhodamine 123 (R123, a substrate for P-gp and BCRP), and
Calcein-AM (a substrate for only P-gp) to study substrate accumulation in the presence of the
potential transport inhibitors and potentially whether it was specific to P-gp or not. If the
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compounds are successful in inhibiting P-gp, substrate will accumulate inside the cell, which can
then be quantitatively measured using the substrate’s fluorescence.
For the Hoechst accumulation assay, compounds 238 and 255 resulted in significantly
accumulated substrate, as seen in Figure 3.15A. All three compounds, 231, 238, and 255, caused
significantly accumulated R123 (Figure 3.15B). Finally, compound 255 resulted in significantly
accumulated Calcein-AM (Figure 3.15C). The differences observed between compound activity
and the three substrates may be due to substrate specificity and level of fluorescence or inherent
errors due to the detection method. These results suggest that these compounds may have the
ability to modulate the activity of P-gp at the BBB, though the results are inconclusive as to the
specificity of these compounds to P-gp and/or BCRP at the BBB.
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A

B

C

Figure 3.15: Accumulation of 29 Variants in BBB Cells.
hCMEC/d3 cells were treated with P-gp substrates Hoechst 33342 (A), Rhodamine 123 (B), or
Calcein-AM (C). Concentrations and procedures are reported in methods. Bars represent the
mean ± SD. NS=not significant (P > 0.05), *P ≤ 0.05, **P≤ 0.01, ***P≤ 0.001, ****P ≤ 0.0001
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CHAPTER 4
DISCUSSION

4.1: BCRP in Reversal of Multidrug Resistance
Multidrug resistance, or MDR, in cancer chemotherapy is often caused by the
overexpression of ABC transporters such as P-glycoprotein (P-gp) and the Breast Cancer
Resistance Protein (BCRP) (Chen et al., 2016) because of their ability to export
chemotherapeutics out of cancerous cells. MDR often leads to recurring cancers and ultimately
poor clinical outcome for patients (Housman et al., 2014). Many different approaches to
overcoming ABC transporter mediated MDR have been studied (Li et al., 2016), one of which
involves using novel inhibitors to stall the efflux action of the transporters that would cause
accumulation of chemotherapeutics in the cancer cells at therapeutically relevant concentrations,
ultimately killing the cancer cells.
Our lab used a unique approach for identifying possible inhibitors for P-gp and BCRP
export pumps. High-throughput in silico ligand docking studies were used to find small, druglike molecules that specifically bind to the nucleotide binding domain (NBD) and reversibly
inhibit ATP hydrolysis by the transporter (Brewer et al., 2014). Previous work in the lab
involved using cell culture methods to test the efficacy of the discovered compounds to reverse
MDR using cancer cell lines that overexpressed P-gp (Follit et al., 2015 and Nanayakkara et al.,
2018. The work presented here expands this research to MDR cancers that overexpress BCRP.
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Results presented in this work help to establish which of our compounds should be
further investigated for potential inhibition of BCRP in order to reverse multidrug resistance. A
previous assay where the fluorescent BCRP substrate Hoechst 33342 was used to demonstrate
substrate accumulation (Nanayakkara, 2019) in BCRP overexpressing cells in the presence or
absence of potential inhibitory experimental compounds identified a group of compounds that
caused accumulation of substrate at least 4-fold compared to DMSO vehicle treated cells. This
group of compounds was dubbed the Top Hits, and it included SMU-50, 53, 70, 71, 83, 103, and
117. A second group of compounds that were close to the 4-fold increase in accumulation cutoff,
called the Almost Hits, included compounds SMU-57, 79, 96, 120, and 124. These compounds
were tested in the three characterized BCRP overexpressing cells lines including M100, S1M180, and MX20.
In studies described here, the following cancer cell lines were used: S1 (human colon
cancer), S1M1-80 (MDR colon cancer resistant to 80 nM mitoxantrone), H460 (human nonsmall cell lung cancer), MX20 (MDR non-small cell lung cancer resistant to 1 nM
mitoxantrone), MCF7 (human breast cancer), and M100 (MDR breast cancer resistant to 100 nM
mitoxantrone). It is necessary to note that the M100 cells used here were specifically low passage
cells, meaning that the cells used were the youngest available at that level of resistance (cell
passage 60). In addition, the M100 cell were not used for more than about 10 passages at a time
to limit any mutations the cells may accumulate that could cause changes in response especially.
The MDR cell lines were characterized at both the RNA and protein levels to confirm
overexpression of BCRP (and in the case of the MX20 cells, slight overexpression of P-gp). It is
necessary to look at expression of ABC transporters at both RNA and protein level due to the
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regulation of these proteins by microRNAs, or miRNAs (Haenisch & Cascorbi, 2012), which can
lead to a discrepancy in the amount of RNA and protein observed.
Cell viability assays were used here to confirm the MDR phenotype exhibited by the
BCRP overexpressing cells, as witnessed by the increased tolerance of overexpressing cells to
higher concentrations of chemotherapeutics compared to their respective parental cells. Cell
viability assays were also used to determine effects of MDR reversal and cytotoxicity of our
potential inhibitory compounds in the three MDR cell lines.
Out of the Top Hits, compounds 70, 71, 83, and 117 reversed MDR in the M100 cells.
For the Almost Hits compound group, all compounds reversed MDR in the M100 cell line.
Compound 79 seemed to re-sensitize M100 cells to mitoxantrone (MNT). However, response to
our compounds differed between the lower (presented here) and higher passage M100 cells. The
previous work done in our lab with the M100 cells (Nanayakkara, 2019) was done with cells at a
higher passage number (cells were used that had been passaged over 90 times).
In this previous work, higher passage M100 cells began to display novel cell
characteristics and responses. In particular, the cells would not display the previously seen
decrease in cell viability when treated with high doses of mitoxantrone. Cells would typically
have a near zero percent cell viability at MNT concentrations of 1 mM, as observed here in
Figure 3.3. In the higher passage M100 cells, the viability would be closer to 20 percent at 1
mM MNT. In addition, the same assay was performed as seen in this work where higher passage
M100 cells were treated with compounds with or without MNT in order to determine the
compounds’ ability to reverse MDR. The higher passage cells suggested that compounds 50, 71
and 117 were the only compounds from the Top Hits group that displayed MDR reversal, while
53, 70, 83 and 103 had significant cytotoxic effects (Nanayakkara, 2019).
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This difference in response between higher and lower passage M100 cells is most likely
due to cell passage effects. Hughes et al. (2018) provides a review of the many different changes
(morphological, response to various drugs, etc.) in several different types of cell lines that occur
between lower and higher passage cells. The American Type Culture Collection (ATCC) also
brings attention to the issue of cell passage effects and states that effects depend on factors such
as species and tissue of origin and culture conditions (ATCC, 2007). Other groups have observed
changes in the proliferation of higher passage and therefore older cells (Peterson et al., 2004), as
well as decreased cellular function (Chung et al., 1999). Thus, work described here compared to
previous work from our group has illustrated the importance of considering the cell passage
number, especially when investigating the response of MDR cancer cells to novel drug-like
compounds combined with chemotherapeutics.
Similar cell viability assays performed in the lower passage M100 cells were also done
with S1M1-80 and MX20 cells. However, results for both the Top Hit and Almost Hit
compounds varied between all three cell lines. None of the Top Hits reversed MDR in the S1M180 cells while only compounds 50 and 70 reversed MDR in MX20 cells. When cells were treated
with the same concentration of compound and a range of concentrations of chemotherapeutic
MNT in order to determine re-sensitization of the cancer cells to the chemotherapeutic,
compound 103 was very cytotoxic in both the S1M1-80 and MX20 cells, 70 was slightly
cytotoxic to both cell lines, 50 was slightly cytotoxic to MX20 cells, and 83 was slightly
cytotoxic to S1M1-80 cells. Also within this assay, compounds 50 and 117 re-sensitized S1M180 cells slightly but not to the same extent as the control Ko143 while 53 performed similarly to
the control. All compounds re-sensitized the MX20 cells, but only compounds 50 and 70 resensitized cells more than Ko143. None of the compounds in the Almost Hits group reversed
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MDR in MX20 or S1M1-80 cells. In both cell lines, compound 79 and MNT treated cells
displayed decreased cell viability compared to MNT only treated cells. Compound 120 was
cytotoxic to S1M1-80 cells. This difference in response between cell lines is an important
observation, as these data suggest that each presenting cancer must be characterized and treated
with inhibitors specific to that cancer.
Many different factors could be contributing to the various responses to the compounds
by the different cell lines. The type of cancer and tissue of origin could play a part. It seems that
one possible explanation for the difference in responses between cell lines is due to the different
level of expression of BCRP. Cells that overexpress BCRP to a greater degree could have a
stronger resistance to chemotherapeutics. It would be interesting to look at one cell line that had
been made to have different levels of BCRP expressed and determine if there are any differences
in response to inhibitors. Since the only difference would be the level of BCRP expression, that
experiment could be helpful in determining if the amount of protein expressed is a contributing
factor to MDR. The experiment presented here in which MX20 cells were treated with tariquidar
in order to effectively inhibit P-gp (Figure 3.11) might also provide another explanation for the
observed differences. When P-gp was inhibited in the MX20 cells, the cells seem to be more
responsive to our compounds. This could mean that the amount of other ABC transporters
expressed in these cells could confound inhibitor studies. However, it is important to note that
the concentration of tariquidar used in this study (500 nM) is well above the reported inhibitory
constant (Ki) of tariquidar (Sugimoto et al., 2013). It would be useful to repeat this experiment
with a lower concentration of tariquidar in order to determine if MX20 could be further
sensitized to mitoxantrone with addition of compounds at this lower concentration of tariquidar.
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Literature remarks on differences between cell lines observed by other groups: Various
miRNAs seem to be inversely regulated in the different MDR cell lines compared to their
respective parental cell lines (Haenisch & Cascorbi, 2012). It also seems that different mutations
in BCRP in the different cell lines that are potentially part of the drug-binding site or that results
in changes in protein structure can lead to variable responses in substrate efflux assays between
cell lines (Honjo et al., 2001). Thus, several different aspects of the cell lines, such as mutations
that have led to overexpression of BCRP or mutations that have led to the cancer, can cause
variable responses in different cell culture assays.
In other work by our group, HFL1 noncancerous cells were used to test the toxicity of our
compounds on more normal cells (Park & Mertz et al., 2020). HFL1 cells have been suggested to
serve as a good model for screening drugs for subacute human chemical toxicity (Yang et al.,
2002). The results of this work indicated that compounds 53, 70, 96, and 124 were not cytotoxic
to HFL1 cells while compounds 83 and 103 were slightly cytotoxic to the noncancerous cells.
Taken together, the research indicated that compounds including 50, 57, 71, 79, 117, and 120
were extremely cytotoxic to HFL1 cells, suggesting that these compounds may not be useful in
future studies due to their extreme cytotoxicity to noncancerous cells which may translate into
toxic side effects in clinical applications. It is important to note that if compounds are not
cytotoxic to noncancerous cells, even if they are cytotoxic to cancer cells, they can and should be
considered for future studies concerning testing of small, drug-like molecules for their ability to
reverse BCRP-mediated drug resistance. In fact, that is a best-case scenario. As long as the toxic
effects on healthy, normal cells are minimized or eliminated completely, cancer cells can and
should experience cytotoxic effects after treatment with inhibitory compounds.
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When the results using multidrug resistant cancer cells presented here are compared with
the results from our compounds tested with noncancerous cells, it seems that compounds 53, 70,
and possibly 83 may be the best overall performers and therefore the most promising candidates
for future studies for BCRP inhibition. Much more research is needed into the mechanism of
action and other aspects of these compounds. However, based on results presented here, it seems
that these small drug-like molecules could serve as early leads to be further developed into cotherapeutics that would allow BCRP-overexpressing cancers to become re-sensitized to
chemotherapeutics. A compound that causes the re-sensitization of cancers to chemotherapeutics
could potentially lead to more successful cancer treatments and less harmful side effects for
patients by allowing smaller doses of chemotherapeutics.
Though cell culture is a reasonable first step in drug discovery due to the ability for highthroughput work and limited costs, the results presented here clearly demonstrate that several
different types of cancer cells should be deeply evaluated and considered before more definitive
conclusions can be made on which lead compounds should be further developed.

4.2: P-gp Inhibition at the Blood-Brain Barrier
ABC transporters such as P-glycoprotein, P-gp, and the Breast Cancer Resistance Protein,
BCRP, are also found to play an important protective role at the blood-brain barrier, or BBB
(Gomez-Zepeda et al., 2019). These transporters are thought to be a major issue when trying to
deliver drugs to the brain to treat diseases because drugs are pumped from the brain before the
disease can be treated (Chavez et al., 2014). Research into inhibitors for P-gp and BCRP at the
BBB has been done, but with limited success. While small molecule drugs may perform well in
vitro, there are many issues related to potency and off-target toxicity that caused failure in animal
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models or early-stage clinical trials (Kalvass et al., 2013). Thus, there remains a need for further
identification and testing of ABC pump inhibitors and their efficacy at the BBB.
A group of small molecules created from an initial promising candidate molecule for Pgp inhibition were synthesized and referred to as 29 variants (Brewer et al, 2014; Follit et al.,
2015; and Nanayakkara et al., 2018), three of which included 231, 238, and 255 (Wise et al.,
2019). These compounds were tested using substrate accumulation assays in hCMEC/d3 brain
capillary endothelium cells. These assays take advantage of fluorescent substrates of P-gp and
BCRP. Upon inhibition of P-gp or BCRP, substrates should accumulate inside the cells, and this
can be measured and quantified by the respective fluorescence of the substrates (Bircsak et al.,
2013). Our experiments indicated that all three compounds tested, 231, 238, and 255, resulted in
accumulation of Rhodamine 123, which is a substrate for both P-gp and BCRP. In contrast, only
238 and 255 resulted in accumulation of Hoechst 33342, which is also a substrate for both P-gp
and BCRP, and only 255 was observed to cause enhanced Calcein-AM retention, which is a
substrate for P-gp only.
Whether these results correlate to potential specificity or cross-specificity between the
two transporters remains to be seen. Other factors affecting the BBB must be considered
including the entire neurovascular unit, such as pericytes and microglia, and how these elements
are communicating with the capillary endothelium (Abbot and Friedman, 2012). Thus, the lack
of clear results from these accumulation assays may be due in part to not considering other cell
types as well as other ABC transporters such as BCRP present at the BBB. Another possible
explanation for these inconclusive results is that there is a low level of expression of BCRP and
P-gp at the BBB, and thus our detection method is not sensitive enough or has too much signal
noise. This work is too preliminary in order to establish whether there is any merit in pursuing
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these compounds at the BBB, and more studies are needed to evaluate whether small molecules
that are found to be P-gp and/or BCRP inhibitors in cancer cell culture also have the ability to
modulate ABC transporters at the blood-brain barrier.

4.3: Future Directions
Due to the protective role of ABC transporters in healthy cells, it is important to consider
several aspects of any potential inhibitor including any non-specific toxicity, specificity to one
certain transporter, any mutations or single nucleotide polymorphisms in the transporter, and
treatment course design. Ideally, a patient’s cancer would be tested for which transporters are
overexpressed and any polymorphisms in the transporter so that an inhibitor designed
specifically for the overexpressed protein with certain mutations would be used for treatment
(Shukla et al., 2011).
All of the presented data regarding BCRP suggest that the best compounds to pursue
likely are 53, 70, and 83. Future studies regarding these three promising compounds for BCRP
inhibition should include using LC-MS/MS to help determine whether these compounds are
likely BCRP substrates or inhibitors. This is an assay that is used to quantify the accumulation of
the compounds in presence or absence of a known BCRP inhibitor such as Ko143, as described
by Nanayakkara (2019). If there is a significance difference in accumulation of a compound in
the presence of an inhibitor, then the compound is likely to be a substrate for BCRP. It would be
interesting to perform this analysis in all three BCRP overexpressing cell lines to determine any
differences in compound behavior depending on cell line. Another way to determine if these
compounds behave as substrates or not is to analyze them using biochemicals methods such as
ATP hydrolysis assays. It is believed that stimulation of basal ATPase activity of a pump such as
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BCRP by a compound is a good indicator that the compound is a substrate (Wang et al., 2006).
Assessing these compounds using purified protein would be useful and necessary for studying
the mechanism of action for these compounds.
P-gp inhibitors were also tested using only the hCMEC/d3 capillary endothelial cell line
as the blood-brain barrier model. Results were inconclusive, most likely due to the experimental
design. Culturing different cell types together in a more representative in vitro assay would be
useful for testing compounds’ inhibition and effect on the entire neurovascular unit (Miller,
2015). Should compounds prove feasible in these assays, then extensive in vivo testing would be
required before moving to clinical trials.
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CHAPTER 5
CONCLUSIONS

Multidrug resistance (MDR) describes when cancers become resistant to more than one
chemotherapeutic, and the drugs the cancers have become resistant to often greatly vary in
structure and mechanism of action. Studies have shown many different mechanisms contribute to
MDR (Baguley, 2010). One such mechanism involves the overexpression of one or more ABC
transporters. These transmembrane proteins act as drug efflux pumps which hydrolyze ATP
inside the cells and conformationally change in order to extrude toxins and xenobiotics from
cells. While this action usually serves as protection for healthy cells, it becomes an issue in
cancers because many chemotherapeutics are substrates for ABC transporters. Cancer drugs are
pumped out of the cancer cells before they have a chance to kill the cells. Two such protein
pumps include P-glycoprotein (P-gp, or ABCB1) and Breast Cancer Resistance Protein (BCRP,
or ABCG2) (Chen et al., 2016).
One way of overcoming ABC transporter mediated drug resistance is finding inhibitors of
the protein that prevent its efflux action. Most approaches involve using transporter substrates
that are preferentially pumped out the cells instead of the chemotherapeutics (Shukla et al.,
2011). However, finding such drugs can be an issue due to the non-specificity of the drug
binding domains (DBDs) of the transporters which can lead to off target toxicities. Instead, our
group took a novel approach in which the nucleotide binding domain (NBD) of the protein is
targeted for inhibition by small drug-like molecules (Brewer et al., 2014).
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Described here is work using three BCRP overexpressing cancer cell lines: M100 (breast
cancer), S1M1-80 (colon cancer), and MX20 (non-small cell lung cancer). These cell lines were
characterized to determine their level of overexpression of BCRP (and slight overexpression of
P-gp in the case of the MX20 cells) on the RNA and protein levels, as well as their MDR
phenotype using cell culture techniques. Two groups of our potential BCRP inhibitor compounds
were tested in these cell lines for their ability to reverse MDR and their cytotoxicity to cancer
cells using cell viability assays. When the results were analyzed, along with other work from the
lab, it was concluded that the most promising candidates for future studies include compounds
SMU-53, 70, and 83.
ABC transporters also play an important role at the blood-brain barrier (BBB), as they
pump toxins and xenobiotics out of the brain. However, this becomes a problem when trying to
deliver drugs to the brain to treat diseases such as brain cancers and epilepsy (Chavez et al.,
2014). If ABC transporters could be specifically targeted and reversibly inhibited at the BBB,
drugs could more easily enter the brain. A group of our P-gp modulators were tested in the
hCMEC/d3 brain capillary endothelial cell line for their ability to accumulate P-gp substrates.
This group of compounds showed promising preliminary results for their ability to negatively
affect the efflux action of P-gp at the BBB.
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